Highest-materiality recent filing
Immunome shareholders elect three Class III directors, ratify auditor, approve say-on-pay
James Boylan elected with 70.2M votes for, 22.2M withheld; Sandra Swain and Philip Wagenheim each received over 92M votes for.
Immunome Q1 2026 net loss $53.8M; NDA filed for varegacestat; cash $582.7M
Net loss of $53.8M; R&D expenses $46.4M (incl. $3.7M stock comp); G&A $13.0M (incl. $4.2M stock comp).
Immunome reports FY2025 net loss $212.4M; cash $653.5M; varegacestat NDA planned Q2 2026
Cash and equivalents $653.5M as of Dec 31, 2025; runway expected into 2028.
Immunome prices $400M public offering of 18.6M shares at $21.50 per share
Public offering of 18,625,000 shares at $21.50/share; gross proceeds ~$400M.
Immunome Phase 3 RINGSIDE trial of varegacestat meets primary endpoint with 84% risk reduction
Progression-free survival HR=0.16 (95% CI 0.071-0.375, p<0.0001) vs placebo in desmoid tumors.
Immunome Q3 net loss $57.5M; cash $272.6M; varegacestat data due by year-end
Net loss of $57.5M for Q3 2025; cash and equivalents $272.6M.
Immunome Q2 net loss $43.4M; cash $268M; varegacestat Phase 3 topline data by end 2025
Net loss of $43.4M for Q2 2025; cash, equivalents and securities $268M as of June 30.
Immunome stockholders elect Barchas and Bienaimé as Class II directors; ratify Ernst & Young
Isaac Barchas elected with 46.3M votes for, 15.2M withheld; Jean-Jacques Bienaimé elected with 47.1M for, 14.4M withheld.
Immunome Q1 net loss $41.6M; cash $317.3M; varegacestat data expected H2 2025
Net loss of $41.6M for Q1 2025; R&D expense $36.9M, G&A $10.7M.
Immunome reports FY 2024 net loss of $293M; cash runway into 2027, pipeline milestones ahead
Net loss $293.0M for FY 2024; cash & equivalents $217.3M at Dec 31, 2024.
Immunome prices upsized $150M public offering of common stock at $7.75/share
19,354,839 shares priced at $7.75 per share; gross proceeds $150M.
Immunome launches public offering of common stock; pipeline update with Phase 3 data H2 2025
Underwritten public offering of common stock commenced; size not disclosed.
CFO Max Rosett receives relocation package with $100K bonus and $300K housing bonus
$100,000 one-time cash relocation bonus paid within 10 days if relocation to Bothell, WA completed by Jan 21, 2026.
Immunome Q3 net loss $47.1M, cash $240.1M; AL102 topline data H2 2025
Net loss of $47.1M for Q3 2024; cash, equivalents and marketable securities $240.1M as of Sept 30, 2024.
Immunome acquires full ownership of ROR1 ADC assets from Zentalis for 1.8M shares plus $5M milestone
Issued 1,805,502 shares of common stock to Zentalis as partial consideration for the asset purchase.
Immunome adopts 2024 Inducement Plan reserving 2M shares for new-hire equity grants
Plan reserves 2,000,000 shares of common stock for inducement awards to new employees.
Immunome reports Q2 2024 net loss of $36.1M; cash $278.4M, runway into 2026
Cash, equivalents and marketable securities totaled $278.4M; expected runway into 2026.
Immunome stockholders elect Siegall and Schafer as Class I directors; E&Y ratified
Clay B. Siegall elected with 43,295,914 votes for, 80,139 withheld; broker non-votes 6,682,195.
Immunome reports Q1 net loss $129.5M; cash $309.7M extends into 2026; AL102 topline data H2 2025
Net loss of $129.5M ($2.51 diluted EPS) includes $112.0M in IPR&D expenses from AL101/AL102 and IM-1021 acquisitions.
Immunome VP Finance/PAO Bob Lapetina resigns; Max Rosett named PAO effective May 10
Bob Lapetina resigned as VP Finance, Corporate Controller and principal accounting officer effective May 10, 2024; departure not due to disagreement.
Immunome appoints Dr. Sandra Swain as Class III director, joins Audit Committee
Appointment effective April 25, 2024; term expires at 2026 annual meeting.
Immunome posts FY2023 net loss of $106.8M; cash $138.1M, AL102 Phase 3 data due Q1 2025
Net loss $106.8M ($5.38 per share) for FY2023; cash and equivalents $138.1M as of Dec 31, 2023 (prior to Feb 2024 $230M offering).
Immunome completes acquisition of Ayala's AL102 Phase 3 desmoid tumor asset for $20M cash + stock
Acquisition of AL102 (Phase 3 gamma secretase inhibitor) and AL101; upfront $20M cash and 2,175,489 shares to Ayala.
Immunome prices $200M follow-on offering of 10M shares at $20/share
Priced 10,000,000 common shares at $20.00 each; gross proceeds ~$200M before expenses.
Preliminary cash, equivalents, and marketable securities of ~$138.1M as of Dec 31, 2023, subject to final close.
Immunome to acquire AL102 Phase 3 desmoid tumor asset from Ayala for $20M cash + $30M stock
Immunome will acquire AL102 and AL101 from Ayala for $20M cash and ~$30M in stock (2.18M shares).
Immunome promotes Max Rosett to EVP, Operations and Interim CFO; grants option for 175k shares
Max Rosett promoted from SVP, Operations and Interim CFO to EVP, Operations and Interim CFO effective Jan 31, 2024.
Immunome plans three INDs by 1Q 2025; closes Zentalis ADC license, Atreca antibody purchase
Zentalis ADC license: $35M upfront (cash+stock), $275M milestones, mid-to-high single digit royalties for ROR1 ADC IM-1021.
Exclusive worldwide license for preclinical ROR1 ADC ZPC-21; IND submission targeted for 1Q 2025.
Immunome appoints Carol Schafer as director, Audit Committee Chair
Carol Schafer appointed Class I director, Chair of Audit Committee, and member of Nominating Committee, effective Jan 2, 2024.
CFO Corleen Roche separates effective Jan 2, 2024; receives 10.5 months salary continuation, $75,000 cash, COBRA coverage, and one-year option exercise extension.
Immunome to acquire Atreca antibody assets for $5.5M upfront plus up to $7M milestones
Upfront cash payment of $5.5 million; additional $7.0 million in clinical development milestones.
Immunome files Morphimmune historical financials: 2022 net loss $7.5M, cash $7.2M
Morphimmune 2022 net loss of $7.5M (2021: $2.8M); accumulated deficit $11.2M as of Dec 31, 2022.
Immunome presents pipeline update; cash runway into Q1 2026; 177Lu-FAP IND planned 1Q25
Cash runway expected into Q1 2026; recently completed $125M PIPE with leading healthcare investors.
Immunome completes Morphimmune merger, $125M PIPE, Q3 net loss $4M
Completed merger with Morphimmune; concurrent $125M oversubscribed PIPE from Enavate Sciences, EcoR1 Capital, Redmile, Janus Henderson, Avidity, Woodline.
Immunome appoints Jean-Jacques Bienaimé as Class II director; initial option grant of $270K
Jean-Jacques Bienaimé appointed as Class II director effective Nov 7, 2023, term through 2025 annual meeting.
Immunome completes merger with Morphimmune, raises $125M PIPE, appoints Clay Siegall as CEO
Merger closed Oct 2, 2023: Morphimmune stockholders received 0.3042 shares per share; 8.84M shares issued.
Immunome discloses merger-related lawsuits and supplemental proxy disclosures
Two securities lawsuits filed by purported stockholders challenging the merger: Weiss v. Immunome (Sept 7) and Thompson v. Immunome (Sept 8).
Immunome Q2 net loss $5.6M; merger with Morphimmune and $125M PIPE deal announced
Q2 net loss $5.6M ($0.46 per share) on $4.3M AbbVie collaboration revenue; R&D $5.7M, G&A $4.2M.
On July 5, 2023, Immunome filed Form 8-K announcing posting of an updated investor presentation on its website.
Immunome merges with Morphimmune; Siegall new CEO; $125M PIPE at $5.75/share
Morphimmune stockholders to own ~45% of combined company; Immunome stockholders ~55% on fully diluted basis.
Immunome shareholders reject officer exculpation amendment at annual meeting
Class III directors Richard A. Baron and Philip Wagenheim elected until 2026.
Immunome reports Q1 2023 net loss of $4.3M; posts $2.4M collaboration revenue from AbbVie deal
Collaboration revenue of $2.4M from AbbVie strategic deal for up to 10 novel antibody-target pairs.
Immunome reports Q4 2022 net loss $7.8M; announces AbbVie collaboration with $30M upfront
Net loss of $7.8M ($0.64 per share) for Q4 2022; full-year net loss $36.9M ($3.09 per share).
Immunome posts corporate presentation on website for investor meetings
Posted presentation dated January 2023 under Item 8.01 of Form 8-K.
Immunome (IMNM) completes first cohort in Phase 1b COVID-19 antibody study; seeks partner
First cohort of Phase 1b study of IMM-BCP-01 (COVID-19 antibody cocktail) dosed with no significant treatment-related adverse events.
Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront
Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.
Immunome posts corporate presentation; details unavailable in filing excerpt
Presentation dated November 15, 2022 posted to company website for investor meetings.
Immunome reports Q3 net loss of $8.5M; cash $27.1M; COVID antibody trial on track
Net loss for Q3 2022 was $8.5 million; no revenue from product sales.
Immunome terminates Deloitte as auditor, appoints Ernst & Young effective Oct 4, 2022
Audit committee terminated Deloitte on Sept 30, 2022; appointed EY effective Oct 4, 2022.
the Company’s board of directors appointed Max Rosett, in addition to his other titles, as the Company’s principal accounting officer effective immediately upon the effectiveness of Mr. Lapetina’s resignation.
Bob Lapetina notified Immunome, Inc. (the “Company”) that he will be resigning from his positions as the Company’s Vice President, Finance, Corporate Controller, and principal accounting officer to pursue other opportunities.
appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.
On January 31, 2024, the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) promoted Max Rosett, the Company’s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer (the “Promotion”).
appointed Carol Schafer as a Class I director of the Company
appointed Bob Lapetina, in addition to his other titles, as the Company’s principal accounting officer.
appointed Max Rosett, in addition to his other titles, as the Company’s Interim Chief Financial Officer and principal financial officer.
Ms. Roche will no longer serve as the Company’s Chief Financial Officer, principal financial officer or principal accounting officer.
appointed Jean-Jacques Bienaimé as a Class II director of the Company
Max Rosett 33 Senior Vice President, Operations
each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors
James Boylan 56 Class III Director
Max materiality 1.00 · Median 0.60 · Most common event other_material